Regulatory Oversight and the Ethics of Essential Medicine Pricing in India

The Supreme Court’s recent intervention regarding the pricing of life-saving drugs has brought the focus back on the structural gaps in India’s pharmaceutical regulatory framework. By highlighting the massive markups between the cost of production and the retail price charged by hospitals, the judiciary has signaled that in the realm of public health, the ‘Right to Life’ under Article 21 must take precedence over pure market-driven economic policies.

At the heart of the issue is the role of the National Pharmaceutical Pricing Authority (NPPA). Tasked with implementing the Drugs (Prices Control) Order, the NPPA is meant to ensure that essential medicines remain affordable. However, the court’s criticism suggests that the current regulatory design is either insufficient or inadequately enforced, allowing healthcare institutions to inflate the prices of critical drugs—such as those used for cancer treatment—by over 1,000 percent. This creates a scenario of ‘predatory pricing’ in a sector where demand is inelastic; patients in life-or-death situations possess zero bargaining power.

This crisis reflects a deeper systemic challenge: the conflict between corporate profit-maximization and the constitutional duty of the state to provide accessible healthcare. When medical inflation outpaces regulatory oversight, the burden of funding social sector services shifts entirely to the vulnerable, potentially pushing millions into poverty. The judiciary’s stance serves as a reminder that regulatory bodies must act not merely as auditors, but as proactive guardians of public interest, ensuring that the pharmaceutical value chain remains equitable.

For effective reform, India needs a more robust mechanism that scrutinizes the entire supply chain—from bulk drug manufacturers to hospital pharmacies. Addressing this requires greater transparency in pricing, strict enforcement of price caps on essential lists (NLEM), and a revision of the current policy approach to better balance market incentives with the principles of social justice and inclusive growth.